Skip to main content

Table 3 Marker levels in patients with highly active antineutrophil cytoplasmic antibody-associated vasculitis before treatment and healthy control subjects

From: Targeted proteomics reveals promising biomarkers of disease activity and organ involvement in antineutrophil cytoplasmic antibody-associated vasculitis

Marker Active AAV (n = 169) Healthy control subjects (n = 30) p Value AUCa COPb Sensitivity Specificity LR + c
CRP, mg/dl 3.79 (0.9–8.24) 0.01 (0.005–0.03) < 0.0001d 0.96 0.16 86 97 25.9
TIMP1, ng/ml 333 (226–426) 132 (115–148) < 0.0001d 0.94 183 86 97 25.9
LRG1, μg/ml 86.1 (53.7–134) 16.3 (13.6–20.7) < 0.0001d 0.97 28.8 93 100
TNC, ng/ml 145 (84.3–265) 48.0 (35.4–64.3) < 0.0001d 0.88 93.1 72 93 10.8
S100A8/A9, μg/ml 5.8 (3.5–8.9) 1.3 (1.1–1.8) < 0.0001d 0.96 2.2 91 93 13.6
CD93, ng/ml 226 (167–300) 125 (103–139) 0.0005d 0.89 149 82 93 12.3
TKT, ng/ml 124 (69.7–183) 33.1 (15.1–42.6) < 0.0001d 0.94 58.1 83 93 12.5
MMP9, ng/ml 791 (429–1382) 517 (294–838) 0.0158d 0.67 642 62 70 2.05
  1. Abbreviations: ANCA Antineutrophil cytoplasmic antibody, COP Cutoff point, CRP C-reactive protein, LR Likelihood ratio, LRG1 Leucine-rich alpha-2-glycoprotein 1, MMP9 Matrix metalloproteinase 9, MPO Myeloperoxidase, TIMP1 Tissue inhibitor of metalloproteinase 1, TKT Transketolase, TNC Tenascin C
  2. Values are median (IQR)
  3. aAn AUC of 1 indicates perfect discrimination between groups; an AUC of 0.5 indicates no discrimination
  4. bCOP is the maximum sum of sensitivity and specificity
  5. cLR+ at the COP, which equals sensitivity/(1 − specificity)
  6. d p < 0.05 by analysis of covariance adjusted for age and sex